FSNR-101011.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Use of a Polyphenol for the Treatment of a Cancerous Or Pre-Cancerous Lesion of the Skin
(19) & (11) EP 2 292 226 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.03.2011 Bulletin 2011/10 A61K 31/353 (2006.01) A61P 17/00 (2006.01) A61P 17/02 (2006.01) A61P 35/00 (2006.01) (21) Application number: 10012395.9 (22) Date of filing: 08.10.2004 (84) Designated Contracting States: (72) Inventor: Stockfleth, Eggert AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 25767 Albersdorf (DE) HU IE IT LI LU MC NL PL PT RO SE SI SK TR (74) Representative: Bösl, Raphael Konrad (30) Priority: 09.10.2003 US 510101 P Isenbruck Bösl Hörschler LLP Patentanwälte (62) Document number(s) of the earlier application(s) in Prinzregentenstrasse 68 accordance with Art. 76 EPC: 81675 München (DE) 04790231.7 / 1 684 780 Remarks: (71) Applicant: MediGene AG This application was filed on 30-09-2010 as a 82152 Martinsried (DE) divisional application to the application mentioned under INID code 62. (54) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin (57) The present invention refers to a method for cancerous or pre-cancerous lesions of the skin by ad- treating cancerous or pre-cancerous lesions of the skin ministering a pharmaceutically effective amount of a by administering a pharmaceutically effective amount of polyphenol to a patient as well as to the production of a a polyphenol to a patient as well as to the production of medicament thereto. a medicament thereto. The present invention refers to a method for treating EP 2 292 226 A2 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 292 226 A2 2 Description that comprise most of the upper layers of skin. -
United States Patent (10) Patent No.: US 9.233,998 B2 Anderson Et Al
US009233998B2 (12) United States Patent (10) Patent No.: US 9.233,998 B2 Anderson et al. (45) Date of Patent: Jan. 12, 2016 (54) NATURAL PRODUCT ANALOGS INCLUDING 5,002,939 A 3, 1991 Streber AN ANTI-NFLAMMLATORY CYANOENONE 5,013,649 A 5/1991 Wang et al. .................. 435/69.1 PHARMACORE AND METHODS OF USE 5,064,823. A 1 1/1991 Lee et al. ...................... 514,198 5,401,838 A 3/1995 Chou ............................ 536,281 (75) Inventors: Eric Anderson, Houston, TX (US); 5,426,183 A 6, 1995 Kjell . 536,285.5 Gary L. Bolton, Ann Arbor, MI (US); 5,464,826 A 11, 1995 Grindey et al. ................. 514,50 Deborah A. Ferguson.g s Branchburg,2. NJ 5,521,294 A 5/1996 Wildfeur ....................... 536,187 (US); Xin Jiang, Dallas, TX (US); 5,597,124. A 1/1997 Kessel et al. .................... 241.30 5,603,958 A 2f1997 Morein et al. ... 424/489 Robert M. Kral, Jr., Grapevine, TX 5,606,048. A 2/1997 Chou et al. ......... 536,271.1 (US); Patrick M. O’Brien, Stockbridge, 5,629,295 A 5/1997 Denimno et al. ................ 514, 26 MI (US); Melean Visnick, Irving, TX 5,972,703 A 10/1999 Long et al. ..... 435/372 (US) 6,025,395 A 2/2000 Breitner et al. ............... 514/570 6,303,569 B1 10/2001 Greenwald et al. ............... 514/2 (73) Assignee: REATA PHARMACEUTICALS, 6,326,507 B1 12/2001 Gribble et al. ..... 558,415 INC. Irving, TX (US) 6,369,101 B1 4/2002 Carlson ....... ... 514,169 6,485,756 B1 1 1/2002 Aust et al. -
Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: in Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary
nutrients Article Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids 1,2, 2, , 1 1 1 Hiroki Saito y, Yu Toyoda * y , Hiroshi Hirata , Ami Ota-Kontani , Youichi Tsuchiya , Tappei Takada 2 and Hiroshi Suzuki 2 1 Frontier Laboratories for Value Creation, Sapporo Holdings Ltd., 10 Okatome, Yaizu, Shizuoka 425-0013, Japan; [email protected] (H.S.); [email protected] (H.H.); [email protected] (A.O.-K.); [email protected] (Y.T.) 2 Department of Pharmacy, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; [email protected] (T.T.); [email protected] (H.S.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 2 July 2020; Accepted: 12 August 2020; Published: 14 August 2020 Abstract: Axillary osmidrosis (AO) is a common chronic skin condition characterized by unpleasant body odors emanating from the armpits, and its aetiology is not fully understood. AO can seriously impair the psychosocial well-being of the affected individuals; however, no causal therapy has been established for it other than surgical treatment. Recent studies have revealed that human ATP-binding cassette transporter C11 (ABCC11) is an AO risk factor when it is expressed in the axillary apocrine glands—the sources of the offensive odors. Hence, identifying safe ways to inhibit ABCC11 may offer a breakthrough in treating AO. We herein screened for ABCC11-inhibitory activities in 34 natural products derived from plants cultivated for human consumption using an in vitro assay system to measure the ABCC11-mediated transport of radiolabeled dehydroepiandrosterone sulfate (DHEA-S—an ABCC11 substrate). -
Different Approaches to Evaluate Tannin Content and Structure of Selected Plant Extracts – Review and New Aspects M
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by JKI Open Journal Systems (Julius Kühn-Institut) Journal of Applied Botany and Food Quality 86, 154 - 166 (2013), DOI:10.5073/JABFQ.2013.086.021 1University of Kiel, Institute of Crop Science and Plant Breeding – Grass and Forage Science / Organic Agriculture, Kiel, Germany 2Institute of Ecological Chemistry, Plant Analysis and Stored Product Protection; Julius Kühn-Institute, Quedlinburg, Germany Different approaches to evaluate tannin content and structure of selected plant extracts – review and new aspects M. Kardel1*, F. Taube1, H. Schulz2, W. Schütze2, M. Gierus1 (Received July 2, 2013) Summary extracts, tannins, salts and derivates was imported to the EU in the year 2011, mainly from Argentina, with a trade value of nearly Tannins occur in many field herbs and legumes, providing an im- 63.5 mio. US Dollar (UN-COMTRADE, 2013). These extracts are pro- mense variability in structure and molecular weight. This leads to duced industrially on a large scale. They could therefore maintain complications when measuring tannin content; comparability of a relatively constant quality and thus provide an advantage in rumi- different methods is problematic. The present investigations aimed at nant feeding. characterizing four different tannin extracts: quebracho (Schinopsis Tannins from different sources can react very diverse regarding lorentzii), mimosa (Acacia mearnsii), tara (Caesalpinia spinosa), protein affinity (MCNABB et al., 1998; BUENO et al., 2008). Diffe- and gambier (Uncaria gambir) and impact of storage conditions. rences in tannin structure can occur even between similar plant Using photometrical methods as well as HPLC-ESI-MS, fundamen- species (OSBORNE and MCNEILL, 2001; HATTAS et al., 2011) and a tal differences could be determined. -
Epigallocatechin Gallate: a Review
Veterinarni Medicina, 63, 2018 (10): 443–467 Review Article https://doi.org/10.17221/31/2018-VETMED Epigallocatechin gallate: a review L. Bartosikova*, J. Necas Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic *Corresponding author: [email protected] ABSTRACT: Epigallocatechin gallate is the major component of the polyphenolic fraction of green tea and is responsible for most of the therapeutic benefits of green tea consumption. A number of preclinical in vivo and in vitro experiments as well as clinical trials have shown a wide range of biological and pharmacological properties of polyphenolic compounds such as anti-oxidative, antimicrobial, anti-allergic, anti-diabetic, anti-inflammatory, anti-cancer, chemoprotective, neuroprotective and immunomodulatory effects. Epigallocatechin gallate controls high blood pressure, decreases blood cholesterol and body fat and decreases the risk of osteoporotic fractures. Further research should be performed to monitor the pharmacological and clinical effects of green tea and to more clearly elucidate its mechanisms of action and the potential for its use in medicine. Keywords: epigallocatechin-3-O-gallate; pharmacokinetics; toxicity; biological activity List of abbreviations ADME = absorption, distribution, metabolism, excretion; AMP = activated protein kinase (AMPK); AUC (0–∞) = area under the concentration-time curve from 0 h to infinity; BAX = apoptosis regulator (pro-apoptotic regulator, known as bcl-2-like protein 4); Bcl-2 = B-cell lymphoma 2; BCL-XL = B-cell -
Exploring Antioxidant Activity, Organic Acid, and Phenolic Composition in Strawberry Tree Fruits (Arbutus Unedo L.) Growing in Morocco
plants Article Exploring Antioxidant Activity, Organic Acid, and Phenolic Composition in Strawberry Tree Fruits (Arbutus unedo L.) Growing in Morocco Hafida Zitouni 1, Lahcen Hssaini 2 , Rachida Ouaabou 3, Manuel Viuda-Martos 4 , Francisca Hernández 5 , Sezai Ercisli 6 , Said Ennahli 7, Zerhoune Messaoudi 7 and Hafida Hanine 1,* 1 Laboratory of Bioprocess and Bio-interfaces, Faculty of Science and Technics, University Sultan Moulay Slimane, BO 523, Beni-Mellal 23000, Morocco; hafi[email protected] 2 Research Unit of Plant Breeding and Plant Genetic Resources Conservation, National Institute for Agricultural Research (INRA), BO 578, Meknes 50000, Morocco; [email protected] 3 LICVEDDE/ERIDDECV (Research Team of Innovation and Sustainable Development & Expertise in Green Chemistry), Faculty of Science Semlalia, Cadi Ayyad University, Marrakesh 40000, Morocco; [email protected] 4 Departamento de Tecnología Agroalimentaria, Tecnología Agroalimentaria, IPOA, Escuela Politécnica Superior de Orihuela, (Universidad Miguel Hernández), Ctra Beniel, km 3.2, E 03312 Orihuela, Spain; − [email protected] 5 Grupo de Investigación de Producción Vegetal y Tecnología, Departamento de Producción Vegetal y Microbiología, Producción Vegetal y Microbiología, Cuela Politécnica Superior de Orihuela (Universidad Miguel Hernández de Elche), Ctra. de Beniel, km 30.2, E 03312 Orihuela, Spain; − [email protected] 6 Department of Horticulture, Agricultural Faculty, Ataturk University, 25240 Erzurum, Turkey; [email protected] 7 Department of Arboriculture, -
Influence of COMT Genotype Polymorphism on Plasma and Urine
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Minnesota Digital Conservancy Influence of COMT Genotype Polymorphism on Plasma and Urine Green Tea Catechin Levels in Postmenopausal Women A THESIS SUBMITTED TO THE FACULTY OF THE UNIVERSITY OF MINNESOTA BY Alyssa Heather Perry IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE Dr. Mindy Kurzer September 2014 © Alyssa Heather Perry 2014 Abstract Catechins are the major polyphenolic compound in green tea that have been investigated extensively over the past few decades in relation to the treatment of various chronic diseases including diabetes, cardiovascular disease, and cancer. O-methylation is a major Phase II metabolic pathway of green tea catechins (GTCs) via the enzyme catechol-O- methyltransferase (COMT). A single nucleotide polymorphism in the gene coding for COMT leads to individuals with a high-, intermediate-, or low-activity COMT enzyme. An epidemiological case-control study suggests that green tea consumption is associated with reduced risk of breast cancer in women with an intermediate- or low-activity COMT genotype. A cross-sectional analysis discovered that men homozygous for the low- activity COMT genotype showed a reduction in total tea polyphenols in spot urine samples compared to the intermediate- and high-activity genotypes. Several human intervention trials have assessed green tea intake, metabolism, and COMT genotype with conflicting results. The aim of the present study was to determine if the COMT polymorphism would modify the excretion and plasma levels of GTCs in 180 postmenopausal women at high risk for breast cancer consuming a green tea extract supplement containing 1222 mg total catechins daily for 12 months. -
Docking Characterization and in Vitro Inhibitory Activity of Flavan-3-Ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2
ORIGINAL RESEARCH published: 30 November 2020 doi: 10.3389/fpls.2020.601316 Docking Characterization and in vitro Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2 Yue Zhu and De-Yu Xie* Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC, United States We report to use the main protease (Mpro) of SARS-Cov-2 to screen plant flavan-3-ols and proanthocyanidins. Twelve compounds, (–)-afzelechin (AF), (–)-epiafzelechin (EAF), (+)-catechin (CA), (–)-epicatechin (EC), (+)-gallocatechin (GC), (–)-epigallocatechin Edited by: (EGC), (+)-catechin-3-O-gallate (CAG), (–)-epicatechin-3-O-gallate (ECG), Guodong Wang, Chinese Academy of Sciences, China (–)-gallocatechin-3-O-gallate (GCG), (–)-epigallocatechin-3-O-gallate (EGCG), Reviewed by: procyanidin A2 (PA2), and procyanidin B2 (PB2), were selected for docking simulation. pro Hiroshi Noguchi, The resulting data predicted that all 12 metabolites could bind to M . The affinity Nihon Pharmaceutical scores of PA2 and PB2 were predicted to be −9.2, followed by ECG, GCG, EGCG, University, Japan Ericsson Coy-Barrera, and CAG, −8.3 to −8.7, and then six flavan-3-ol aglycones, −7.0 to −7.7. Docking Universidad Militar Nueva characterization predicted that these compounds bound to three or four subsites (S1, Granada, Colombia S1′, S2, and S4) in the binding pocket of Mpro via different spatial ways and various *Correspondence: De-Yu Xie formation of one to four hydrogen bonds. In vitro analysis with 10 available compounds pro [email protected] showed that CAG, ECG, GCG, EGCG, and PB2 inhibited the M activity with an IC50 value, 2.98 ± 0.21, 5.21 ± 0.5, 6.38 ± 0.5, 7.51 ± 0.21, and 75.3 ± 1.29 µM, Specialty section: respectively, while CA, EC, EGC, GC, and PA2 did not have inhibitory activities. -
WO 2011/086458 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... _ 21 July 2011 (21.07.2011) WO 2011/086458 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61L 27/20 (2006.01) A61L 27/54 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/IB20 11/000052 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 13 January 201 1 (13.01 .201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 12/687,048 13 January 2010 (13.01 .2010) US (84) Designated States (unless otherwise indicated, for every 12/714,377 26 February 2010 (26.02.2010) US kind of regional protection available): ARIPO (BW, GH, 12/956,542 30 November 2010 (30.1 1.2010) us GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): AL- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, LERGAN INDUSTRIE, SAS [FR/FR]; Route de EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Promery, Zone Artisanale de Pre-Mairy, F-74370 Pringy LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (FR). -
Experimental Section
N° d’ordre : 4542 THÈSE PRÉSENTÉE A L’UNIVERSITÉ BORDEAUX 1 ÉCOLE DOCTORALE DES SCIENCES CHIMIQUES Par Daniela Melanie DELANNOY LOPEZ POUR OBTENIR LE GRADE DE DOCTEUR SPÉCIALITÉ : CHIMIE ORGANIQUE Synthèse de dérivés de polyphénols bioactifs pour l’étude de leurs interactions avec des protéines Directeur de recherche : Pr. Stéphane Quideau Soutenue le : 02 Juillet 2012 Après avis de : Mme RENARD, C. Directrice de Recherche, INRA-Avignon Rapporteur M. MONTI J. Professeur Universite de Bordeaux 2 Rapporteur Devant la commission d’examen formée de : Mme RENARD, C. Directrice de Recherche, INRA-Avignon Rapporteur M. MONTI J. Professeur Universite de Bordeaux 2 Rapporteur M. GENOT E. Group leader, IECB Université Bordeaux 2 Présidente M. Di Primo C. Chargé de recherche, Université Bordeaux Examinateur M. DEFFIEUX, D. Maître de conférence, Université Bordeaux 1 Co-directeur de thèse M. QUIDEAU, S. Professeur, Université Bordeaux 1 Directeur de thèse Table of Contents Acknowledgements…………………………………………………………………...………5 Résumé en français…………………………………..……………………………………….8 List of communications………………………….………………………………………….12 Introduction……………..…………………………………………………………………...13 Chapter I. Polyphenol-Protein Interactions ........................................................................ 16 Ia. Polyphenols ................................................................................................................... 17 Ia.1 Physico-chemical properties of polyphenols ............................................................... 24 Ia.2 Antioxidant/Pro-oxidant -
(12) Patent Application Publication (10) Pub. No.: US 2005/0079235A1 Stockfleth (43) Pub
US 20050079235A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0079235A1 Stockfleth (43) Pub. Date: Apr. 14, 2005 (54) USE OF A POLYPHENOL FOR THE Publication Classification TREATMENT OF ACTINIC KERATOSIS (51) Int. Cl.' ..................... A61K 35/78; A61K 31/7048; (76) Inventor: Eggert Stockfleth, Berlin (DE) A61K 31/353 (52) U.S. Cl. ............................. 424/729; 514/456; 514/27 Correspondence Address: CLARK & ELBING LLP 101 FEDERAL STREET (57) ABSTRACT BOSTON, MA 02110 (US 9 (US) The present invention refers to a method for treating actinic (21) Appl. No.: 10/682,612 keratosis by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the (22) Filed: Oct. 9, 2003 production of a medicament thereto. US 2005/0079235 A1 Apr. 14, 2005 USE OF A POLYPHENOL FOR THE TREATMENT the later development of Squamous cell carcinoma. They OF ACTINIC KERATOSIS include actinic keratoses, actinic cheilitis, leukoplakia and Bowen's disease. BACKGROUND OF THE INVENTION 0006 Actinic keratosis (AK), also known as a solar keratosis, arises on the skin Surface. AK appears as rough, 0001. The present invention refers to a method for treat Scaly crusty and/or slightly raised growths that range in ing actinic keratosis by administering a pharmaceutically color from brown to red and may be up to one inch in effective amount of a polyphenol to a patient as well as to the diameter. It appears most often in older people. The base production of a medicament thereto. may be light or dark, tan, pink, red or a combination of these 0002 Skin cancer is a disease in which malignant (can or has the same color as the skin itself. -
Condensed Tannins in Extracts from European Medicinal Plants and Herbal Products
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Central Archive at the University of Reading Condensed tannins in extracts from European medicinal plants and herbal products Article Accepted Version Ropiak, H. M., Ramsay, A. and Mueller-Harvey, I. (2016) Condensed tannins in extracts from European medicinal plants and herbal products. Journal of Pharmaceutical and Biomedical Analysis, 121. pp. 225-231. ISSN 0731-7085 doi: https://doi.org/10.1016/j.jpba.2015.12.034 Available at http://centaur.reading.ac.uk/49645/ It is advisable to refer to the publisher's version if you intend to cite from the work. To link to this article DOI: http://dx.doi.org/10.1016/j.jpba.2015.12.034 Publisher: Elsevier All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading's research outputs online 1 Condensed tannins in extracts from European medicinal plants and herbal products 2 3 Honorata M. Ropiak*, Aina Ramsay, Irene Mueller-Harvey* 4 5 Chemistry and Biochemistry Laboratory, School of Agriculture, Policy and Development, 6 University of Reading, P O Box 236, Reading RG6 6AT, UK 7 8 *Corresponding author: [email protected], [email protected] 9 10 ABSTRACT 11 Medicinal plant materials are not usually analysed for condensed tannins (CT).